Commentary

What Is Psychocutaneous Medicine? [editorial]

Cutis. 2007 October;80(4):273-
By
Silverberg NB
Author and Disclosure Information

No abstract available.
PDF Download

 

Recommended Reading

But Enough About You
MDedge Dermatology
New Anticancer Agents Have Distinctive Toxicities
MDedge Dermatology
Phase III Trial Activity for Melanoma Is Robust : Biologics being studied include CTLA4 blockers, apoptosis restorers, and antiangiogenesis agents.
MDedge Dermatology
Current Options in Stage IV Melanoma Deemed Unsatisfactory
MDedge Dermatology
Sorafenib Results Mixed For Advanced Melanoma
MDedge Dermatology
Plant-Based Compound Shows Efficacy Against Basal Cell Ca
MDedge Dermatology
Wine Analogy May Help Patients Grasp Filler Menu
MDedge Dermatology
FDA Approval of Reloxin Predicted Within Year
MDedge Dermatology
Cosmetic Result Analysis Depends On the Evaluator
MDedge Dermatology
Combined Therapy Optimizes Facial Rejuvenation
MDedge Dermatology